PT-141 10mg Vial

PT-141 was the development code given to a small synthetic peptide that is now known by its nonproprietary name, bremelanotide. It is a ring-shaped (cyclic) seven-residue peptide built on the alpha-melanocyte-stimulating hormone (alpha-MSH) template, which places it in the melanocortin family of signalling molecules.

The three names are often blurred together online, so it helps to separate them. PT-141 is the research code. Bremelanotide is the molecule. Vyleesi is a branded prescription product containing bremelanotide that the U.S. FDA approved in June 2019. Remy Research uses the Vyleesi label and the FDA review file only as official reference sources for the molecule's pharmacology and safety record.

This vial is not Vyleesi and is not a medicine of any kind. It is freeze-dried bremelanotide research material from the ProPeptide line, which Remy Research sells strictly as bench and animal-model material. For research use only. Not for human or veterinary use.

The listing is a single sealed vial of powder. Here is what that format gives a laboratory, and what is and is not documented for it today.

Freeze-dried powder for storage stability

The vial holds 10mg of lyophilised (freeze-dried) bremelanotide under a crimped seal. Peptides keep far better as dry powder than in solution, which is why the vial remains the default way research peptides are stored and shipped. For the chemistry behind that, see the peptide stability and storage guide.

The purity line, and what has been published

ProPeptide states a purity standard of 99% or higher by HPLC for this line. No batch-specific independent report for the PT-141 10mg vial has been published yet, and we will not suggest otherwise. The one PT-141 report currently in our lab results library belongs to the 20mg pen batch, not to this vial.

What a good certificate should show

Two separate questions matter: is the sample pure (an HPLC trace answers that) and is it really bremelanotide (a mass spectrum near 1025.2 answers that). Look too for the lab's name, a test date and a batch code that matches the vial. Each of these items is unpacked in the COA and HPLC purity guide.

Chilled delivery within the UAE

Each parcel is packed to hold 2–8°C in transit, and a Dubai order in before 4 PM reaches you that day. Cut-off times for the other six emirates are on the delivery page.

Vial or pen?

The same peptide is also listed as a PT-141 20mg pen. The vial suits work that starts from dry, sealed material; the pen is a separate, pre-filled format with its own published batch report.

Bremelanotide entered the literature as a tool for probing melanocortin circuits in the brain. The points below summarise what published papers and the official U.S. label report. They describe study findings, not effects anyone should expect.

A melanocortin agonist, not a PDE5-type compound

Early development papers, including Molinoff and colleagues in 2003, describe agonist activity at melanocortin receptors including MC3R and MC4R, which are tied mainly to central nervous system signalling. That sets the molecule apart from sildenafil-class drugs, which act on the nitric oxide and PDE5 vascular pathway.

MC1R and pigmentation

The Vyleesi label adds evidence of activity at MC1R, the receptor on pigment-producing skin cells, and lists increased focal pigmentation as an observed effect. So the receptor picture is broad rather than selective.

How the human studies progressed

The clinical record moved in three steps: small placebo-controlled intranasal studies around 2004, a randomized placebo-controlled trial in premenopausal women published in 2016 that compared several exposure levels, and two phase 3 RECONNECT trials in premenopausal women with hypoactive sexual desire disorder, published in 2019. Those trials reported changes on validated questionnaire endpoints under controlled conditions. They concern the approved product in one defined patient group.

Recorded tolerability signals

The safety observations that recur across the primary studies and the label are short-lived rises in blood pressure (examined with ambulatory monitoring in a 2017 study), nausea, and focal darkening of the skin. For the approved product, the label gives a terminal half-life near 2.7 hours, with blood levels peaking around the one-hour mark.

A related compound: Melanotan II

Bremelanotide is structurally close to Melanotan II and is often described as a metabolite of it, but the two have different receptor emphasis and very different evidence trails. Our PT-141 vs Melanotan II comparison sets out the differences, and the PT-141 melanocortin research review covers the full literature with references.